Table 3.
Exosome Function | Origin of exosomes | Recipient cells | Effect | Potential targets | Ref. |
---|---|---|---|---|---|
Immunosuppression | Ascites of OC patients | T cells | Arrest T cells | GD3, TCR | [46] |
Ascites of OC patients | Monocytes | Cytokine production | TLR signaling pathways | [47] | |
Ascites of OC patients | PBMCs and DCs | Apoptosis | FasL | [27] | |
Ascites of OC patients | T cells | Apoptosis | FasL | [54] | |
OC cells | T cells | Counterattack against activated T cells | LPA and FasL | [55] | |
Ovarian tumor tissues | T cells | T cell inhibition | Depletion or blockade of PS | [56] | |
EOC cells and ascites | NK cells | Cytotoxicity inhibition | NKG2D | [57] | |
Angiogenesis | OC cells | HUVECs | Affect VEGF or HIF-1α | ATF2 and MTA1 | [58] |
OC cells | HUVECs | CD147 stimulates VEGF expression | CD147 | [59] | |
OC cells | HUVECs | Activate β-catenin and NF-κB signaling | sE-cad | [60] | |
Stroma remodeling | OC cells | ADSCs | Transition ADSCs to CAFs | α-SMA, SDF-1, TGF-β SMAD2 and PI3K/AKT pathway | [67] |
OC cells | Macrophages | Macrophage M2 polarization | miR-21–3p, miR-125b-5p, and miR-181d-5p SOCS4/5/ STAT3 pathway | [41] |
Abbreviations: OC ovarian cancer, GD 3 ganglioside 3, TCR T-cell receptor, TLR Toll-like receptor, PBMCs peripheral blood lymphocytes, DCs dendritic cells, FasL Fas ligand, LPA Lysophosphatidic acid, PS phosphatidylserine, EOC Epithelial ovarian cancer, NK natural killer, HIF Hypoxia-inducible factor, HUVECs Human umbilical vein endothelial cells, sE-cad soluble E-cadherin, ADSCs adipose tissue-derived mesenchymal stem cells, α-SMA alpha-smooth muscle actin, SDF-1 stromal cell-derived factor 1, PI3K Phosphoinositide 3-kinases, AKT Protein kinase B, SOCS Suppress cytokine signaling, STAT3 Signal transducer and activator of transcription 3